Skip to main content
. 2020 May 16;50(4):559–563. doi: 10.1016/j.semarthrit.2020.04.015

Table 1.

Characteristics of two IgG4-RD patients with COVID-19.

Basic information Patient 1 Patient 2 The last follow-up Patient 1 Patient 2
Age (y) 58 45 IgG4 (g/L) 11.4 4.19
Gender Male Male T-IgE (<100) 477.9 14.65
History of IgG4-RD (y) 2 1.5 CD3+CD19-(955-2860) 985 966
IgG4-RD RI (the first follow up) 18 15 CD3+CD8+(320-1250) 209 271
IgG4-RD RI (the last follow up) 1 6 CD3+CD4+ (550-1440) 744 634
Biological agents No No CD3-CD19+ (90-560) 127 149
Prednisone (mg/d) 5 5 NK (150-1100) 1473 1423
Symptoms Comorbidities
Fever Yes Yes Hypertension No No
Cough Yes Yes Cardiovascular disease No No
Fatigue Yes Yes Diabetes Yes No
Diarrhea No No Tumor No No
Lab findings Complications
PT, s (10-16) 13.5 15.4 ARDS No No
D-dimer, mg/L (0-0.5) 0.58 0.16 Shock No No
Albumin, g/L (40-55) 33.1 42.3 Acute cardiac injure No No
ALT, U/L (9-50) 118 77 Acute liver injure Yes Yes
AST, U/L (15-40) 36 36 Acute kidney injure No No
LDH, U/L (120-250) 330 66.1 Electrolyte disorder Yes Yes

Abbreviations: PT, prothrombin time, ALT, alanine aminotransferase, LDH, lactic dehydrogenase, AST, aspartate transaminase, ARDS, acute respiratory distress syndrome, IgG4-RD, IgG4 related disease.